These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 20410546)

  • 41. Vaccination for quality of life: herpes-zoster vaccines.
    Lang PO; Aspinall R
    Aging Clin Exp Res; 2021 Apr; 33(4):1113-1122. PubMed ID: 31643072
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The impact of herpes zoster and post-herpetic neuralgia on quality-of-life.
    Johnson RW; Bouhassira D; Kassianos G; Leplège A; Schmader KE; Weinke T
    BMC Med; 2010 Jun; 8():37. PubMed ID: 20565946
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Zoster Vaccine and the Risk of Postherpetic Neuralgia in Patients Who Developed Herpes Zoster Despite Having Received the Zoster Vaccine.
    Tseng HF; Lewin B; Hales CM; Sy LS; Harpaz R; Bialek S; Luo Y; Jacobsen SJ; Reddy K; Huang PY; Zhang J; Anand S; Bauer EM; Chang J; Tartof SY
    J Infect Dis; 2015 Oct; 212(8):1222-31. PubMed ID: 26038400
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Vaccination for preventing postherpetic neuralgia.
    Chen N; Li Q; Zhang Y; Zhou M; Zhou D; He L
    Cochrane Database Syst Rev; 2011 Mar; (3):CD007795. PubMed ID: 21412911
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term efficacy data for the recombinant zoster vaccine: impact on public health and cost effectiveness in Germany.
    Curran D; Van Oorschot D; Matthews S; Hain J; Salem AE; Schwarz M
    Hum Vaccin Immunother; 2021 Dec; 17(12):5296-5303. PubMed ID: 34905463
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effectiveness of herpes zoster vaccination in an older United Kingdom population.
    Walker JL; Andrews NJ; Amirthalingam G; Forbes H; Langan SM; Thomas SL
    Vaccine; 2018 Apr; 36(17):2371-2377. PubMed ID: 29555217
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Herpes zoster vaccination: benefits and barriers.
    Komara FA
    J Am Osteopath Assoc; 2009 Jun; 109(6 Suppl 2):S22-4. PubMed ID: 19553633
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Herpes zoster vaccine effectiveness and manifestations of herpes zoster and associated pain by vaccination status.
    Marin M; Yawn BP; Hales CM; Wollan PC; Bialek SR; Zhang J; Kurland MJ; Harpaz R
    Hum Vaccin Immunother; 2015; 11(5):1157-64. PubMed ID: 25806911
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Vaccines against Herpes zoster: Effectiveness, safety, and cost/benefit ratio].
    Ferahta N; Achek I; Dubourg J; Lang PO
    Presse Med; 2016 Feb; 45(2):162-76. PubMed ID: 26724874
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Herpes Zoster and its prevention in Italy. Scientific consensus statement].
    Franco E; Gabutti G; Bonanni P; Conversano M; Stefano Valente ME; Ferro A; Icardi G; Antonio Volpi ML; Maggi S; Rossi A; Scotti S; Vitale F; Greco D;
    Ig Sanita Pubbl; 2014; 70(1):111-27. PubMed ID: 24770367
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Herpes zoster vaccine awareness among people ≥ 50 years of age and its implications on immunization.
    Javed S; Javed F; Mays RM; Tyring SK
    Dermatol Online J; 2012 Aug; 18(8):2. PubMed ID: 22948052
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Herpes Zoster Vaccination: Controversies and Common Clinical Questions.
    Van Epps P; Schmader KE; Canaday DH
    Gerontology; 2016; 62(2):150-4. PubMed ID: 26184711
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A randomized, placebo-controlled phase I trial of live, attenuated herpes zoster vaccine in subjects with end-stage renal disease immunized prior to renal transplantation.
    Miller G; Schaefer H; Yoder S; Miller R; Winokur P; Kotloff K; Klassen D; Wierzbicki M; Amegashie C; Edwards K
    Transpl Infect Dis; 2018 Jun; 20(3):e12874. PubMed ID: 29512282
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of efficacy and effectiveness of live attenuated zoster vaccine.
    Gabutti G; Valente N; Sulcaj N; Stefanati A
    J Prev Med Hyg; 2014 Dec; 55(4):130-6. PubMed ID: 26137786
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Active immunoprophylaxis to reduce clinical impact of Herpes Zoster and its complications].
    Marino MG; Bagnato B; Torella I; Franco E
    Ig Sanita Pubbl; 2009; 65(3):299-311. PubMed ID: 19629155
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older.
    Cunningham AL; Lal H; Kovac M; Chlibek R; Hwang SJ; Díez-Domingo J; Godeaux O; Levin MJ; McElhaney JE; Puig-Barberà J; Vanden Abeele C; Vesikari T; Watanabe D; Zahaf T; Ahonen A; Athan E; Barba-Gomez JF; Campora L; de Looze F; Downey HJ; Ghesquiere W; Gorfinkel I; Korhonen T; Leung E; McNeil SA; Oostvogels L; Rombo L; Smetana J; Weckx L; Yeo W; Heineman TC;
    N Engl J Med; 2016 Sep; 375(11):1019-32. PubMed ID: 27626517
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Herpes Zoster and Its Prevention by Vaccination.
    Johnson RW; Levin MJ
    Interdiscip Top Gerontol Geriatr; 2020; 43():131-145. PubMed ID: 32305975
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vaccine profile of herpes zoster (HZ/su) subunit vaccine.
    Cunningham AL; Heineman T
    Expert Rev Vaccines; 2017 Jul; 16(7):1-10. PubMed ID: 28486850
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Review of the Persistence of Herpes Zoster Vaccine Efficacy in Clinical Trials.
    Cook SJ; Flaherty DK
    Clin Ther; 2015 Nov; 37(11):2388-97. PubMed ID: 26602282
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Analysis of real-world health care costs among immunocompetent patients aged 50 years or older with herpes zoster in the United States.
    Meyers JL; Madhwani S; Rausch D; Candrilli SD; Krishnarajah G; Yan S
    Hum Vaccin Immunother; 2017 Aug; 13(8):1861-1872. PubMed ID: 28605285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.